RADX Radiopharm Theranostics Ltd


$ 5.26 $ 0.09 (1.74 %)    

Friday, 31-Oct-2025 15:59:50 EDT
QQQ $ 629.16 $ 3.02 (0.48 %)
DIA $ 475.58 $ 0.66 (0.14 %)
SPY $ 681.80 $ 2.23 (0.33 %)
TLT $ 90.21 $ -0.27 (-0.3 %)
GLD $ 368.20 $ -2.01 (-0.54 %)
$ 5.26
$ 5.28
$ 4.98 x 10
$ 6.00 x 66
$ 4.98 - $ 5.31
$ 3.50 - $ 50.82
16,239
na
na
$ 0.68
na
TBD
na
na (na)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Preliminary data from first three patients in Phase 2b imaging clinical trial of RAD 101 show uptake in brain metastases from s...

Core News & Articles

Financial updateThe following is a summary of the Appendix 4C Cash Flow Report:The year-end closing cash balance was $29.12 mil...

Core News & Articles

- Radiopharm Theranostics (ASX: RAD, NASDAQ:RADX, "Radiopharm" or the "Company"), a clinical-stage biopharmaceu...

Core News & Articles

Radiopharm Theranostics (ASX: RAD, NASDAQ:RADX, &, ldquo, Radiopharm&, rdquo, or the &, ldquo, Company&, rdquo,...

Core News & Articles

Brookline Capital analyst Kemp Dolliver initiates coverage on Radiopharm Theranostics (NASDAQ:RADX) with a Buy rating and an...

Core News & Articles

RAD 402 preclinical data package complete; demonstrates safety and promising biodistribution profileEthics approval and Phase 1...

Core News & Articles

Radiopharm Theranostics (ASX:RAD, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company fo...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION